Sodium-glucose co-transporter 2 (SGLT2) inhibitors, a newly listed type of hypoglycemic drug, not only effectively lower blood glucose levels and improve cardiovascular risk factors of diabetic patients (i.e., reducing weight, blood pressure, and blood lipid and uric acid levels) but also effectively delay the disease progression of diabetic patients with CKD (19, 20). The gene discussed is SLC5A2; the disease is chronic kidney disease.